SRR5088890
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- MYC_TARGETS_V1+0.400
- PROTEIN_SECRETION+0.400
- ADIPOGENESIS+0.300
- MYC_TARGETS_V2+0.300
- E2F_TARGETS+0.200
- FATTY_ACID_METABOLISM+0.200
- PEROXISOME+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- DNA_REPAIR+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- INFLAMMATORY_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- ANGIOGENESIS-0.400
- COAGULATION-0.400
- COMPLEMENT-0.400
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088889 | — | — | 0.961 |
| 2 | 15d39440-6bb8-4ecb-add1-9ae8b007dc70 | — | — | 0.915 |
| 3 | BS_VA5T4KAA | medulloblastoma | — | 0.909 |
| 4 | R6 | — | — | 0.905 |
| 5 | BS_HKZENFDA | medulloblastoma | — | 0.903 |
| 6 | SRR1797243 | — | cohortSC | 0.903 |
| 7 | TCGA-BH-A0H0-01A-11R-A056-07 | — | B | 0.902 |
| 8 | SRR1467364 | GTEX | — | 0.900 |
| 9 | BS_NKEAAFMW | medulloblastoma | — | 0.899 |
| 10 | SRR1797277 | — | cohortSC | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |